CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medifocus Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medifocus Inc.
The Exchange Tower
Suite 1800, 130 King Street West,
Phone: (905) 319-7070p:905 319-7070 TORONTO, ON  M5X 1E3  Canada Fax: (905) 517-6060f:905 517-6060

On 8/12/2022, the Company was acquired by Asset Profits Limited.
This company is no longer actively traded on any major stock exchange.

Business Summary
Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company’s APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20193/31/2019YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director William W.Jow 10/1/2016 3/1/2016
Corporate Executive JohnMon 3/1/2016 1/1/2012
Independent Director Shuen C.Chan 70 1/1/2010 1/1/2010
Independent Director AugustineChow 69 1/1/2010 1/1/2010
Independent Director RaymondTong 1/1/2017 8/31/2016

Business Names
Business Name
Celsion (Canada) Inc.
Medifocus Inc.
MFS
MFS.H
Prolieve

General Information
Outstanding Shares: 184,984,215 (As of 12/31/2019)
Stock Exchange: NEX
Federal Tax Id: 980607537
Fax Number: (905) 517-6060


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023